Most Read Articles
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.

Immunosuppressive therapy for IMID does not worsen disease in COVID-19 patients

03 Dec 2020

A recent study has shown that immunosuppressive (IS) therapies for immune-mediated inflammatory diseases (IMIDs) do not increase the risk of SARS-CoV-2 or severe sequelae when controlling for other factors. In addition, tumour necrosis factor α inhibitors may lower the risk of severe infection.

“Finite clinical data and understanding of COVID-19 immunopathology has led to limited, opinion-based recommendations for the management of IMID [patients] receiving IS therapeutics,” the authors said.

A retrospective cohort analysis was performed to determine if IS therapeutic type influences COVID-19 risk among IMID patients. Participants included Henry Ford Health System patients who tested positive for COVID-19 between 1 February and 18 April 2020 and were treated with IS medication for IMID.

Then, the authors combined the therapeutic class of IS medication, comorbidities, and demographic factors into multivariate models to determine the predictors of COVID-19 infection, admission, ventilation, and mortality.

A total of 213 patients with IMID were included, of whom 36.2 percent tested positive for COVID-19. Of note, these patients were not more likely to be hospitalized or need ventilation relative to the general population.

IS therapeutic did not exacerbate the course of disease after multivariate correction, but multidrug regimens and biologics were predictive of an increased and decreased rate of hospitalization, respectively, with the latter driven by tumour necrosis factor α inhibitors.

“A single-centre study somewhat limits the generalization to community-based settings. Only patients tested for COVID-19 were analysed,” the authors noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pank Jit Sin, 13 May 2020
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier. 
Jairia Dela Cruz, 18 Dec 2020
Rinsing with mouthwash that contains povidone-iodine (PI) or cetylpyridinium chloride (CPC) helps reduce SARS-CoV-2 levels in the saliva of COVID-19 patients, with the effect persisting for up to 6 hours, as shown in a study from Singapore.